Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases.

Biomolecules - 14 Dec 2021

Vlasenkova Ramilia, Nurgalieva Alsina, Akberova Natalia, Bogdanov Mikhail, Kiyamova Ramziya

Abstract excerpt

The main goal of this study is to consider SLC34A2 as a potential prognostic marker of oncological diseases using the mutational, expression, and survival data of cancer studies which are publicly available online. We collected data from four databases (cBioPortal, The Cancer Genome Atlas; cBioPortal, Genie; International Cancer Genome Consortium; ArrayExpress). In total, 111,283 samples were categorized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Databases, Genetic
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to INDEL Mutation

Share to Mutation, Missense

Share to Neoplasms

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 34944522
DOI: 10.3390/biom11121878
PMCID: PMC8699446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases.PMID 34944522Read ↗

High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.Semantic proximity Read ↗

SLC11A2: a promising biomarker and therapeutic target in ovarian cancerSemantic proximity Read ↗

Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.Semantic proximity Read ↗

A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancerSemantic proximity Read ↗

A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancerSemantic proximity Read ↗

Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) in Pan-CancerSemantic proximity Read ↗

SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.Semantic proximity Read ↗

Comprehensive analyses of solute carrier family members identify SLC12A2 as a novel therapy target for colorectal cancer.Semantic proximity Read ↗

Comprehensive bioinformatics analysis of the solute carrier family and preliminary exploration of SLC25A29 in lung adenocarcinomaSemantic proximity Read ↗

Systematic Pan-Cancer Analysis Identifies SLC31A1 as a Biomarker in Multiple Tumor TypesSemantic proximity Read ↗

A new combined prognostic model involving SLC44A4 improves the predictive ability for colorectal cancer patientsSemantic proximity Read ↗

Mitochondria-associated gene SLC25A32 as a novel prognostic and immunotherapy biomarker: From pan-cancer multi-omics analysis to breast cancer validationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.